Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
Sherry Shen, Maria M. Rubinstein, Kay J. Park, Jason Konner, Vicky Makker
Abstract
• Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer. • KRAS mutations are characteristic in patients with endometrial MLA. • We report two cases of KRAS -mutated endometrial MLA with excellent and durable responses to lenvatinib and pembrolizumab. • Tumors with KRAS mutations may be particularly sensitive to lenvatinib, but this warrants further study.
Topics & Concepts
LenvatinibKRASMedicinePembrolizumabEndometrial cancerOncologyAdenocarcinomaInternal medicineCancer researchMesonephric ductCancerColorectal cancerImmunotherapyThyroid cancerKidneyUrinary and Genital Oncology StudiesRenal and related cancersRenal cell carcinoma treatment